Taken together, our results from both genetic and pharmacological approaches support the notion that Slc4a4 governs astrocyte-endothelial interaction by regulating the CCL2-CCR2 pathway under stroke conditions, providing insights into therapeutic implication of CCL2 inhibition in stroke associated with Slc4a4 dysfunction. This evidence concerns the gene SLC4A4 and stroke disorder.